Peer review process
Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors.
Read more about eLife’s peer review process.Editors
- Reviewing EditorChristof Niehrs
- Senior EditorDidier StainierMax Planck Institute for Heart and Lung Research, Bad Nauheim, Germany
Reviewer #1 (Public Review):
In this ms, Tejeda-Muñoz and colleagues examine the roles of macropinocytosis in WNT signalling activation in development (Xenopus) and cancer (CRC sections, cell lines and xenograft experiments). Furthermore, they investigate the effect of the inflammation inducer Phorbol-12-myristate-13-acetate (PMA) in WNT signalling activation through macropinocytosis. They propose that macropinocytosis is a key driver of WNT signalling, including upon oncogenic activation, with relevance in cancer progression.
I found the analyses and conclusions of the relevance of macropinocytosis in WNT signalling compelling, notably upon constitutive activation both during development and in CRC. However, I think this manuscript only partially characterises the effects of PMA in WNT signalling, largely due to a lack of an epistatic characterisation of PMA roles in Wnt activation. For example:
1- The authors show that PMA cooperate with 1) GSK3 inhibition in Xenopus to promote WNT activation, and 2) (possibly) with APCmut in SW480 to induce b-cat and FAK accumulation. To sustain a specific functional interaction between WNT and PMA, the effects should be tested through additional epistatic experiments. For example, does PMA cooperate with Wnt8 in axis duplication analyses? Does PMA cooperate with any other WNT alteration in CRC or other cell lines? Importantly, does APC re-introduction in SW480 rescue the effect of PMA? Such analyses could be critical to determine specificity of the functional interactions between WNT and PMA. This question could be addressed by performing classical epistatic analyses in cell lines (CRC or HEK) focusing on WNT activity, and by including rescue experiments targeting the WNT pathway downstream of the effects e.g., dnTCF, APC re- introduction, etc.
2- While the epistatic analyses of WNT and macropinocytosis are clear in frog, the causal link in CRC cells is contained to b-catenin accumulation. While is clear that macropinocytosis reduces spheroid growth in SW480, the lack of rescue experiments with e.g., constitutive active b-catenin or any other WNT perturbation or/and APC re-introduction, limit the conclusions of this experiment.
Minor comments:
3- Different compounds targeting membrane trafficking are used to rescue modes of WNT activation (Wnt8 vs LiCl) in Xenopus.
4- The abstract does not state the results in CRC/xenografts
5- Labels of Figure 2E might be swap
6- Figure 4i,j, 6 and s4 rely on qualitative analyses instead of quantifications, which underscores their evaluation. On the other hand, the detailed quantifications in Figure S3A-D strongly support the images of Figure 5
Reviewer #2 (Public Review):
Tejeda Muñoz et al. investigate the intersection of Wnt signaling, macropinocytosis, lysosomes, focal adhesions and membrane trafficking in embryogenesis and cancer. Following up on their previous papers, the authors present evidence that PMA enhances Wnt signaling and embryonic patterning through macropinocytosis. Proteins that are associated with the endo-lysosomal pathway and Wnt signaling are co-increased in colorectal cancer samples, consistent with their pro-tumorigenic action. The function of macropinocytosis is not well understood in most physiological contexts, and its role in Wnt signaling is intriguing. The authors use a wide range of models - Xenopus embryos, cancer cells in culture and in xenografts and patient samples to investigate several endolysosomal processes that appear to act upstream or downstream of Wnt. A downside of this broad approach is a lack of mechanistic depth. In particular, few experiments monitor macropinocytosis directly, and macropinocytosis manipulations have pleiotropic effects that are open alternative interpretations. Several experiments are confirmatory of previous findings; the manuscript could be improved by focusing on the novel relationship between PMA-induced macropinocytosis and better support these conclusions with additional experiments.
The authors use a range of inhibitors that suppress macropinosome formation (EIPA, Bafilomycin A1, Rac1 inhibition). However, these are not specific macropinocytosis inhibitors (EIPA blocks an Na+/H+ exchanger, which is highly toxic and perturbs cellular pH balance; Bafilomycin blocks the V-ATPase, which has essential functions in the Golgi, endosomes and lysosomes; Rac1 signals through multiple downstream pathways). A specific macropinocytosis inhibitor does not exist, and it is thus important to support key conclusions with dextran uptake experiments.
The title states that PMA increases Wnt signaling through macropinocytosis. However, the mechanistic relationship between PMA-induced macropinocytosis and Wnt signaling is not well supported. The authors refer to a classical paper that demonstrates macropinocytosis induction by PMA in macrophages (PMID: 2613767). Unlike most cell types, macrophages display growth factor-induced and constitutive macropinocytic pathways (PMID: 30967001). It would thus be important to demonstrate macropinocytosis induction by PMA experimentally in Xenopus embryos / cancer cells. Does treatment with EIPA / Bafilomycin / Rac1i decrease the dextran signal in embryos? In macrophages, the PKC inhibitor Calphostin C blocks macropinocytosis induction by PMA (PMID: 25688212). Does Calphostin C block macropinocytosis in embryos / cancer cells? Do the various combinations of Wnts / Wnt agonists and PMA have additive or synergistic effects on dextran uptake? If the authors want to conclude that PMA activates Wnt signaling, it would also be important to demonstrate the effect of PMA on Wnt target gene expression.
The experiments concerning macropinosome formation in Xenopus embryos are not very convincing. Macropinosomes are circular vesicles whose size in mammalian cells ranges from 0.2 - 10 µM (PMID: 18612320). The TMR-dextran signal in Fig. 1A does not obviously label structures that look like macropinosomes; rather the signal is diffusely localized throughout the dorsal compartment, which could be extracellular (or perhaps cytosolic). I have similar concerns for the cell culture experiments, where dextran uptake is only shown for SW480 spheroids in Fig. S2. It would be helpful to quantify size of the circular structures (is this consistent with macropinosomes?).
In Fig. 4I - J, the dramatic decrease in b-catenin and especially in Rac1 after overnight EIPA treatment is rather surprising. How do the authors explain these findings? Is there any evidence that macropinocytosis stabilizes Rac1? Could this be another effect of EIPA or general toxicity?
On a similar note, Fig. 6 K - L the FAK staining in control cells appears to localize to focal adhesions, but in PMA-treated cells is strongly localized throughout the cell. Do the authors have any thoughts on how PMA stabilizes FAK and where the kinase localizes under these conditions? Does PMA treatment increase FAK signaling activity?
The tumor stainings in Figure 5 are interesting but correlative. Pak1 functions in multiple cellular processes and Pak1 levels are not a direct marker for macropinocytosis. In the discussion, the authors discuss evidence that the V-ATPase translocates to the plasma membrane in cancer to drive extracellular acidification. To which extent does the Voa3 staining reflect lysosomal V-ATPase? Do the authors have controls for antibody specificity?
Reviewer #3 (Public Review):
The manuscript by Tejeda-Munoz examines signaling by Wnt and macropinocytosis in Xenopus embryos and colon cancer cells. A major problem with the study is the extensive use of pleiotropic inhibitors as "specific" inhibitors of macropinocytosis in embryos. It is true that BafA and EIPA block macropinocytosis, but they do many other things as well. A major target of EIPA is the NheI Na+/proton transporter, which also regulates invasive structures (podosomes, invadopodia) which could have major roles in development. Similarly, Baf1 will disrupt lysosomes and the endocytic system, which secondary effects on mTOR signaling and growth factor receptor trafficking. The authors cannot assume that processes inhibited by these drugs demonstrate a role of macropinocytosis. While correlations in tumor samples between increased expression of PAK1 and V0a3 and decreased expression of GSK3 are consistent with a link between macropinocytosis and Wnt-driven malignancy, the cell and embryo-based experiments do not convincingly make this connection. Finally, the data on FAK and TES are not well integrated with the rest of the manuscript.
1. The data in Fig. 1A do not convincingly demonstrate macropinocytosis - it is impossible to tell what is being labeled by the dextran.
2. The data in Fig. 2 do not make sense. LiCL2 bypasses the WNT activation pathway by inhibiting GSK3. If subsequent treatment with BafA blocks the effects of GSK3 inhibition, then BafrA is doing something unrelated to Wnt activation, whose target is the inhibition/sequestration of GSK3. While BafA might block GSK3 sequestration by inhibiting MVB function, it should have no effect on the inhibition of GSK3 by LiCl2.
3. The effect of EHT on MP in SW480 cells is not clearly related to what is happening in the embryos. The nearly total loss of staining for Rac and -catenin after overnight EIPA does not implicate MP in protein stability - critical controls for cell viability and overall protein turnover are absent. Inhibition of WNT signaling might be expected to enhance -catenin turnover, but the effect on Rac1 is surprising. A more quantitative analysis by western blotting is required.
4. The data on FAK inhibition and TES trafficking are poorly integrated with the rest of the paper.